Patents by Inventor Pamela Danagher

Pamela Danagher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7264799
    Abstract: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: September 4, 2007
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: D. Clark Bennett, Elizabeth Cauchon, Dominique Fink, Brigette Grouix, Ariane Hsia, Pamela Danagher, Joseph F. Zimmermann
  • Publication number: 20060140928
    Abstract: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.
    Type: Application
    Filed: February 22, 2006
    Publication date: June 29, 2006
    Applicant: Biomarin Pharmaceutical Inc.
    Inventors: D. Bennett, Elizabeth Cauchon, Dominique Fink, Brigette Grouix, Ariane Hsia, Pamela Danagher, Joseph Zimmermann
  • Publication number: 20050191288
    Abstract: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.
    Type: Application
    Filed: May 2, 2005
    Publication date: September 1, 2005
    Applicant: Biomarin Pharmaceutical Inc.
    Inventors: D. Bennett, Elizabeth Cauchon, Dominique Fink, Brigette Grouix, Ariane Hsia, Pamela Danagher, Joseph Zimmermann
  • Publication number: 20010006635
    Abstract: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.
    Type: Application
    Filed: September 27, 1996
    Publication date: July 5, 2001
    Inventors: D. CLARK BENNETT, ELIZABETH CAUCHON, DOMINIQUE FINK, BRIGETTE GROUIX, ARIANE HSIA, PAMELA DANAGHER, JOSEPH ZIMMERMANN
  • Patent number: 5997863
    Abstract: Glycosaminoglycans, including heparinases 1, 2 and 3 as well as chondroitinases AC and B from the Gram negative bacteria Flavobacterium heparinum, can be used either separately or in combination to manipulate cell proliferation. In one embodiment, heparinases are administered to degrade heparan sulfate components of the extracellular matrix, thereby allowing the heparin binding growth factors which are stored in the extracellular matrix to migrate to adjacent cells. The mobility of chemoattractant agents, growth factors and cells also can be increased by treating tissues with glycosaminoglycan degrading enzymes, both chondroitinases and heparinases. The enzymatic removal of chondroitin sulfates from cell surfaces effectively increases the availability of growth factor receptors on the cell's surface. Selectively removing heparan sulfate from cell surfaces while leaving the extracellular matrix intact, conversely, inhibits cell proliferation by down regulating the cell's response to growth factors.
    Type: Grant
    Filed: July 8, 1994
    Date of Patent: December 7, 1999
    Assignee: Ibex Technologies R and D, Inc.
    Inventors: Joseph Zimmermann, Israel Vlodavsky, Clark Bennett, Pamela Danagher, Richard Broughton